Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Nov 8:67:155-157.
doi: 10.1016/j.jdcr.2025.10.066. eCollection 2026 Jan.

Dual immunomodulator therapy with upadacitinib and bimekizumab in severe hidradenitis suppurativa: A case report

Kenan Kherallah  1 , Claire S Chung  1 , Justin Gillenwater  2 , Edward C Jones-López  3 , Vivian Y Shi  4 , Jennifer L Hsiao  5 , Katrina H Lee  5
Affiliations
Case Reports

Dual immunomodulator therapy with upadacitinib and bimekizumab in severe hidradenitis suppurativa: A case report

Kenan Kherallah et al. JAAD Case Rep. .
No abstract available

Keywords: bimekizumab; biologics; hidradenitis suppurativa; small molecule inhibitor; upadacitinib.

PubMed Disclaimer

Conflict of interest statement

Dr Shi is on the board of directors for the Hidradenitis Suppurativa Foundation (HSF), an advisor for the National Eczema Association, is a stock shareholder of Learn Health and has served as an advisory board member, investigator, speaker, and/or received research funding from Sanofi Genzyme, Regeneron, AbbVie, Genentech, Eli Lilly, Novartis, SUN Pharma, LEO Pharma, Pfizer, Incyte, Dermavant, Apogee, MoonLake, Navigator Medicine, Boehringer Ingelheim, Almirall, Alumis, Aristea Therapeutics, Menlo Therapeutics, Dermira, Burt’s Bees, Galderma, Kiniksa, UCB, Ceraclere, Bain Capital, Target-PharmaSolutions, Castle Bioscience, Altus Lab/cQuell, MYOR, Polyfins Technology, GpSkin, and Skin Actives Scientific. Dr Hsiao is on the board of directors for the HS Foundation and has served as an advisor, investigator, and/or speaker for AbbVie, Amgen, Aclaris, Boehringer Ingelheim, Galderma, Incyte, Insmed, Moonlake, Navigator Medicines, Novartis, Pfizer, Sanofi, Regeneron, and UCB. Dr Lee has served as an investigator or advisor for Novartis and Incyte. The other authors have no conflicts of interest to declare.

Figures

Fig 1
Fig 1
Numerous inflamed nodules and interconnected draining tunnels involving the thighs, inguinal folds, perineum, and scrotum prior to the initiation of upadacitinib.
Fig 2
Fig 2
Quiescent nondraining tunnels, atrophic scarring, and postsurgical scarring of the thighs, inguinal folds, perineum, and scrotum after 18 months of dual immunomodulatory therapy.
See this image and copyright information in PMC

References

    1. Esmann S., Jemec G.B.E. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol. 2011;91(3):328–332. doi: 10.2340/00015555-1082. - DOI - PubMed
    1. Ingram J.R., Woo P.N., Chua S.L., et al. Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality. Br J Dermatol. 2016;174(5):970–978. doi: 10.1111/bjd.14418. - DOI - PMC - PubMed
    1. Sabat R., Alavi A., Wolk K., et al. Hidradenitis suppurativa. Lancet. 2025;405(10476):420–438. doi: 10.1016/s0140-6736(24)02475-9. - DOI - PubMed
    1. Maronese C.A., Ingram J.R., Marzano A.V. Has the time come to assess small-molecule/biologic drug combinations for the management of moderate-to-severe hidradenitis suppurativa? Br J Dermatol. 2023;189(4):467–468. doi: 10.1093/bjd/ljad224. - DOI - PubMed
    1. Elizalde-Hernández P.D., Solis-González A.J., Méndez-Flores F.L., Estrada-Aguilar L. [Hidradenitis suppurativa, report with dual therapy: small molecules and biological therapy] Rev Med Inst Mex Seguro Soc. 2025;63(2) doi: 10.5281/zenodo.14617170. - DOI - PMC - PubMed

Publication types

LinkOut - more resources